Navigation Links
West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
Date:9/4/2012

LIONVILLE, Pa., Sept. 4, 2012 /PRNewswire/ -- West (NYSE: WST), a leading global manufacturer of components and systems for injectable drug delivery, today announced an agreement with Janssen Biotech, Inc. to collaborate on the development and manufacturing of an innovative self-injection product. The technology, developed by Janssen Biotech, has been specifically designed to meet the needs of patients by facilitating easier self-injection of pharmaceutical and biologic drug products. West will market the new injection technology under the name SelfDose™ (http://www.selfdose.com/).

(Logo: http://photos.prnewswire.com/prnh/20120904/NE65950LOGO )

West will be responsible for co-developing and handling the commercial scale-up and manufacture of the product, and will have the ability to offer the SelfDose injection technology as part of its expanding portfolio of self-injection technology platforms. The SelfDose injection technology complements West's ConfiDose® and SmartDose® injection technologies, and offers a solution for improved manual injection.

Providing the best solution to the challenges of packaging and delivering today's sensitive and complex biopharmaceutical products requires not only an effective drug container, but also a delivery system that can enable safe, effective and reliable delivery of the medication, especially when the administrator may be a patient. The SelfDose injection technology can help meet these challenges.

"We are delighted to have formalized our relationship with Janssen Biotech around this drug delivery platform and look forward to working together to commercialize the SelfDose injection technology, providing manufacturing, development and regulatory support through the remainder of the process," said Donald E. Morel, Jr., Ph.D., West's Chairman and CEO. "We value the opportunity to strengthen our long-standing relationship and are excited by this agreement. We look forward to working with Janssen to help them meet their business goals to restore health and serve patients."

About West

West's innovative system, device and component solutions help improve the safety and administration of injectable drugs. West's proprietary materials science, formulation research and manufacturing technologies advance the quality, therapeutic value, development speed and rapid market availability of pharmaceuticals, biologics and vaccines. Sales in 2011 totaled US$1.2 billion. West supports its customers from sales, manufacturing, customer support and research and development from locations in North and South America, Europe, Asia and Australia. Global headquarters are in Lionville, Pa., USA. Visit West online at http://www.westpharma.com. Follow West on Twitter: http://www.twitter.com/WestPharma

SelfDose™ is a trademark of West.

ConfiDose® is a registered trademark of West Pharmaceutical Services, Inc. in the United States and other jurisdictions.

SmartDose® is a registered trademark of Medimop Medical Projects Ltd., a subsidiary of West Pharmaceutical Services, Inc.

Media Contact:
Kristin Villiotte
Schwartz MSL
(781) 684-0770
westpharma@schwartzmsl.com

Investor Contact:
Michael A. Anderson
Vice President and Treasurer
(610) 594-3345
Michael.Anderson@westpharma.com

 


'/>"/>
SOURCE West
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
2. TeleTracking Announces Real-Time Locating System (RTLS) Contract with Geisinger Health
3. VirtualScopics Announces Receipt of Notice from Nasdaq
4. VLST Corporation Announces In-licensing Agreement with Pfizer for Anti-CD40 Monoclonal Antibody
5. Sihuan Pharmaceutical Announces 2012 Interim Results
6. Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
7. Elbit Imaging Ltd. Announces Second Quarter Results for 2012
8. SkinMedica Announces Collaboration Agreement with Massachusetts General Hospital for Research and Development of Pigmentation Products
9. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
10. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
11. MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriters Option to Purchase Additional Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):